CXCR2 antagonists for the treatment of pulmonary disease
- 31 October 2008
- journal article
- review article
- Published by Elsevier BV in Pharmacology & Therapeutics
- Vol. 121 (1), 55-68
- https://doi.org/10.1016/j.pharmthera.2008.10.005
Abstract
No abstract availableKeywords
This publication has 191 references indexed in Scilit:
- Characterisation of the range of neutrophil stimulating mediators in cystic fibrosis sputumThorax, 2008
- Treatment with DF 2162, a non‐competitive allosteric inhibitor of CXCR1/2, diminishes neutrophil influx and inflammatory hypernociception in miceBritish Journal of Pharmacology, 2008
- Socs3 maintains the specificity of biological responses to cytokine signals during granulocyte and macrophage differentiationExperimental Hematology, 2008
- Profound functional and signaling changes in viable inflammatory neutrophils homing to cystic fibrosis airwaysProceedings of the National Academy of Sciences of the United States of America, 2008
- The Th17–ELR+ CXC chemokine pathway is essential for the development of central nervous system autoimmune diseaseThe Journal of Experimental Medicine, 2008
- Blockade of the chemokine receptor CXCR2 ameliorates adjuvant‐induced arthritis in ratsBritish Journal of Pharmacology, 2008
- Pulmonary CXCR2 regulates VCAM-1 and antigen-induced recruitment of mast cell progenitorsProceedings of the National Academy of Sciences of the United States of America, 2007
- Cystic fibrosis: the mechanisms of pathogenesis of an inherited lung disorderDrug Discovery Today: Disease Mechanisms, 2007
- Bronchial mucosal inflammation and upregulation of CXC chemoattractants and receptors in severe exacerbations of asthmaThorax, 2007
- Differential regulation of the CXCR2 chemokine network in rat brain trauma: Implications for neuroimmune interactions and neuronal survivalNeurobiology of Disease, 2006